Blood cancers are diagnosed through a layered process that typically starts with routine blood tests and moves into more specialized procedures like bone marrow biopsies, genetic testing, and imaging. No single test confirms a blood cancer on its own. Instead, doctors piece together results from several sources to identify the exact type and subtype, which directly shapes treatment. The full diagnostic workup can take anywhere from a few days to several weeks.
Blood Tests: The First Signal
Most blood cancer diagnoses begin with a complete blood count, or CBC. This test measures your red blood cells, white blood cells, and platelets. Blood cell levels that are abnormally high or low can raise suspicion for leukemia, lymphoma, or other blood cancers. A CBC alone can’t confirm a diagnosis, but it’s often what prompts further testing.
Doctors may also order blood protein tests, which look for unusual proteins circulating in your blood. Elevated levels of certain proteins can point toward blood cancers like multiple myeloma or lymphoma. For multiple myeloma specifically, doctors look for a pattern of organ damage sometimes called CRAB: high calcium levels, reduced kidney function, anemia (low red blood cells), and bone lesions visible on imaging. Meeting these criteria alongside abnormal bone marrow findings is what establishes the diagnosis.
Bone Marrow Biopsy
If blood tests suggest a blood cancer, the next step is often a bone marrow biopsy. This is one of the most important diagnostic procedures for leukemia and multiple myeloma, and it’s sometimes used for lymphoma as well. The procedure involves collecting a small sample of bone marrow, usually from the back of your hip bone.
You’ll receive local anesthesia to numb the skin and the tissue down to the bone surface. A specialized needle is then inserted into the bone to withdraw a tiny amount of marrow, roughly a third of a milliliter. Drawing only this small volume matters because larger samples get diluted with regular blood, which can compromise the results. In some cases, a small core of solid bone tissue is also removed for examination.
The samples are sent to a pathologist, who examines the cells under a microscope after staining them with dyes that highlight cellular details. But microscopic appearance is just one piece of the puzzle. Portions of the sample are also sent for genetic analysis and a technique called flow cytometry, which identifies cancer cells based on the specific proteins sitting on their surface.
Flow Cytometry: Identifying Cancer Cell Types
Flow cytometry works by passing individual cells through a laser beam after tagging them with fluorescent markers that bind to specific surface proteins. The pattern of proteins a cancer cell carries acts like a fingerprint, telling doctors exactly what type of blood cancer they’re dealing with.
For B-cell lymphomas and leukemias, cells that carry one protein called CD5 tend to fall into categories like chronic lymphocytic leukemia or mantle cell lymphoma. Cells carrying a different protein called CD10 are more commonly seen in follicular lymphoma or certain aggressive large-cell lymphomas. Some cancers lack both of these markers entirely, pointing instead toward marginal zone lymphoma or other subtypes. These distinctions matter because different subtypes behave differently and respond to different treatments.
Flow cytometry results are typically available faster than genetic testing, often within a few days, giving doctors an early read on the cancer type while they wait for more detailed molecular results.
Genetic and Chromosomal Testing
Blood cancers are increasingly defined by their genetic profile, not just how the cells look under a microscope. Two key techniques help map these genetic changes.
The first is karyotyping, which produces an image of all 46 chromosomes in a cell to spot large-scale abnormalities. The second is a test called FISH (fluorescence in situ hybridization), which uses fluorescent probes to detect specific genetic changes. FISH can identify three main types of chromosomal problems: extra copies of a gene (amplifications), segments of a chromosome that have broken off and reattached in the wrong place (translocations), and missing stretches of DNA (deletions). These changes are used to diagnose leukemia, lymphoma, and multiple myeloma, and they also help predict how aggressive the cancer is likely to be.
For certain blood cancers, specific mutations are essentially required to make the diagnosis. Chronic myeloid leukemia, for example, is defined by a translocation between chromosomes 9 and 22. Myeloproliferative neoplasms like polycythemia vera or essential thrombocythemia require testing for mutations in genes like JAK2, MPL, or CALR using highly sensitive assays that can detect the mutation even when it’s present in as few as 1 in 100 cells. Modern classification systems integrate these genetic findings with cell appearance and clinical symptoms to arrive at a precise diagnosis.
Genetic results take longer than other tests. Samples sometimes need to be sent to specialized laboratories, and results can take several weeks to come back.
Lymph Node Biopsy for Lymphoma
Lymphoma is primarily diagnosed through a biopsy of an enlarged lymph node rather than a bone marrow sample. The preferred approach is a surgical excision, where the entire lymph node (or a large portion of it) is removed. This matters more than it might seem. A large French study reviewing over 32,000 lymphoma cases found that surgical excision provided a definitive diagnosis 98.1% of the time, compared to 92.3% for core needle biopsies, which use a thicker needle to extract a small cylinder of tissue.
Core needle biopsies were nearly 18 times more likely to yield insufficient material for diagnosis (1.8% vs. 0.1%). They also had higher rates of misclassification between cancerous and non-cancerous conditions. Certain lymphoma subtypes, particularly some T-cell lymphomas, were essentially impossible to diagnose correctly on a core needle biopsy alone in the study. When a core needle biopsy is inconclusive, doctors will typically recommend a full surgical excision to get a clear answer.
Imaging: PET and CT Scans
Imaging plays a central role in lymphoma diagnosis and staging, and it’s also used for multiple myeloma. The most valuable tool is the PET-CT scan, which combines two types of imaging. The CT portion shows the size and location of lymph nodes and other structures. The PET portion reveals metabolic activity, essentially highlighting areas where cells are consuming more energy than normal, a hallmark of active cancer.
This combination is particularly useful because not every enlarged lymph node is cancerous, and not every abnormality on a CT scan needs treatment. In one study of advanced Hodgkin lymphoma patients, 20 people had suspicious-looking lesions on CT that showed no increased metabolic activity on PET. Five of those lesions never changed during treatment, confirming they weren’t lymphoma at all. In another case, PET-CT downstaged a patient’s cancer because a lung nodule that looked suspicious on CT showed no metabolic uptake, meaning it was unlikely to be lymphoma. Changes in metabolic activity are considered more meaningful than changes in lymph node size when assessing whether treatment is working.
Liquid Biopsy: A Newer Tool
Liquid biopsy, which analyzes fragments of DNA shed by cancer cells into the bloodstream, is beginning to play a role in blood cancer detection. It’s not yet a standard first-line diagnostic tool for blood cancers, but it can uncover them unexpectedly. In a study of patients with solid tumors who underwent routine liquid biopsy, 7.7% carried genetic mutations considered high-risk for blood disorders. Among those referred to a blood cancer specialist, half had a confirmed blood cancer that had been previously undetected, including myelodysplastic syndrome and Waldenström macroglobulinemia.
For now, liquid biopsy is more commonly used for monitoring known blood cancers or identifying targetable mutations than for initial diagnosis. But its ability to catch hidden cancers through a simple blood draw suggests its role will continue to grow.
How Long the Process Takes
The timeline from first abnormal blood test to a confirmed, subtyped diagnosis varies. Basic biopsy results, where a pathologist examines stained tissue under a microscope, typically take one to two weeks. Flow cytometry results may come back somewhat faster. Genetic and chromosomal testing takes the longest, sometimes several weeks, because samples may need to be sent to specialized labs with trained scientists and specific equipment.
In urgent cases, such as suspected acute leukemia, preliminary results from blood tests and flow cytometry can guide treatment within days. But a complete diagnosis that includes the genetic profile and precise subtype, which is essential for choosing the right long-term treatment, often takes three to four weeks from the initial biopsy.